| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
46,864 |
16,848 |
$3.02M |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
21,668 |
8,063 |
$454K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
21,184 |
8,674 |
$397K |
| P9603 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled |
14,545 |
7,841 |
$240K |
| 84443 |
Thyroid stimulating hormone (TSH) |
9,274 |
6,883 |
$130K |
| 80053 |
Comprehensive metabolic panel |
16,490 |
10,209 |
$129K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
22,526 |
13,352 |
$115K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
7,143 |
5,411 |
$74K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,310 |
633 |
$56K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
9,144 |
6,927 |
$50K |
| 85610 |
|
13,738 |
5,168 |
$46K |
| 80061 |
Lipid panel |
9,469 |
6,986 |
$41K |
| 82533 |
|
3,316 |
2,438 |
$36K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
4,141 |
3,132 |
$31K |
| 84436 |
|
5,190 |
3,932 |
$29K |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
12,027 |
6,285 |
$26K |
| 84479 |
|
4,234 |
3,140 |
$22K |
| 85651 |
|
5,732 |
3,550 |
$22K |
| 82607 |
|
1,938 |
1,486 |
$21K |
| 83735 |
|
3,473 |
1,829 |
$20K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,135 |
1,672 |
$19K |
| 81001 |
|
6,646 |
4,492 |
$17K |
| 87075 |
|
1,789 |
1,414 |
$16K |
| 87184 |
|
2,237 |
1,659 |
$15K |
| 82043 |
|
4,072 |
3,058 |
$14K |
| 82746 |
|
1,245 |
992 |
$13K |
| 82728 |
|
1,296 |
1,001 |
$9K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
37 |
37 |
$9K |
| 36415 |
Collection of venous blood by venipuncture |
15,507 |
7,899 |
$9K |
| 83540 |
|
1,451 |
1,117 |
$8K |
| 82985 |
|
644 |
514 |
$8K |
| 84153 |
|
712 |
535 |
$7K |
| 84439 |
|
848 |
678 |
$7K |
| 80164 |
|
788 |
586 |
$6K |
| 82570 |
|
1,408 |
1,191 |
$6K |
| G2024 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source |
392 |
211 |
$6K |
| 83880 |
|
273 |
169 |
$5K |
| 86140 |
|
1,108 |
466 |
$4K |
| 86141 |
|
264 |
83 |
$4K |
| 85730 |
|
448 |
360 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
47 |
24 |
$2K |
| 86706 |
|
167 |
114 |
$2K |
| 86803 |
|
128 |
93 |
$2K |
| 84550 |
|
490 |
366 |
$2K |
| 83550 |
|
192 |
128 |
$1K |
| 86704 |
|
103 |
71 |
$1K |
| 87340 |
|
92 |
64 |
$991.80 |
| 84480 |
|
98 |
74 |
$902.25 |
| 86328 |
|
48 |
33 |
$892.40 |
| 86708 |
|
121 |
86 |
$885.70 |
| 86703 |
|
43 |
31 |
$764.26 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
20 |
13 |
$745.60 |
| 84100 |
|
275 |
141 |
$707.59 |
| 84155 |
|
149 |
125 |
$272.67 |
| 80076 |
|
77 |
48 |
$256.81 |
| 86705 |
|
20 |
13 |
$250.18 |
| 86694 |
|
19 |
13 |
$210.87 |
| 84154 |
|
14 |
14 |
$185.31 |
| 86709 |
|
21 |
14 |
$90.91 |
| 83721 |
|
12 |
12 |
$0.00 |